AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

By Lisa Pauline Mattackal and Shashwat Chauhan (Reuters) -UK shares ended higher on Monday after logging their worst day ...

The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

AstraZeneca PLC AZN shares dropped 1.66% to £115.84 Monday, on what proved to be an all-around great trading session for the ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

The approved indication involves using durvalumab in combination with chemotherapy as a neoadjuvant treatment, followed by ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...

UK shares ended higher on Monday, driven by gains in commodity-linked shares, particularly precious metal miners, amidst rising gold prices. Heavyweight energy shares also tracked elevated crude oil ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...

James Gordon has given his Buy rating due to a combination of factors surrounding AstraZeneca’s position in the market and the assessment of their drug development pipeline. Firstly, despite the final ...

AstraZeneca plc (AZN, AZN.L) announced on Monday that the high-level results from the TROPION-Breast01 Phase III trial of datopotamab ...